Therapeutic potential of non-competitive, subtype-selective metabotropic glutamate receptor ligands

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 12, 2002, Pages 1845-1852

  Mutel, Vincent ^a  

^a ADDEX PHARMACEUTICALS   (Switzerland)

Author keywords

Allosteric modulator; Anxiety; Inverse agonist; Metabotropic glutamate (mGlu) receptor; Migraine; Neuropathic pain; Non competitive ligands; Schizophrenia

Indexed keywords

(9H XANTHENE 9 CARBONYL)CARBAMIC ACID BUTYL ESTER; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 5 METHYLENE 6A (NAPHTHALEN 2 YLMETHYL)HEXAHYDROCYCLOPENTANE[C]FURAN 1 ONE; 6 AMINO N CYCLOHEXYL N,3 DIMETHYLTHIAZOLO[3,2 A]BENZIMIDAZOLE 2 CARBOXAMIDE; 7 (HYDROXYLIMINO)CYCLOPROPAN[B]CHROMEN 1A CARBOXYLIC ACID ETHYL ESTER; AMIDE; BAY 36 720; CARBAMIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; EGLUMETAD; GLUTAMIC ACID; LACTONE DERIVATIVE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N (1H INDAN 2 YL) 2 (2 HYDROXYETHYLTHIO) 5,6,7,8 TETRAHYDROQUINAZOLIN 4 AMINE; NEUROTRANSMITTER; OXAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; BRAIN TISSUE; DRUG DESIGN; DRUG DETERMINATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; MAMMAL; NONHUMAN; REVIEW;

EID: 0036931925     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.12.1845     Document Type: Review

References (26)

1. BOCKAERT J, PIN JP: Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. (1999) 18(7):1723-1729.
2. PARMENTIER ML, PREZEAU L, BOCKAERT J, PIN JP: A model for the functioning of family 3 GPCRs. Trends Pharmacol. Sci. (2002) 23(6):268-274.
3. SCHOEPP DD: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. (2001) 299(1):12-20.
4. SCHOEPP DD, JANE DE, MONN JA: Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology (1999) 38(10):1431-1476.
5. PAGANO A, RUEGG D, LITSCHIG S et al.: The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem. (2000) 275(43):33750-33758.
6. LITSCHIG S, GASPARINI F, RUEEGG D et al.: CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signalling without affecting glutamate binding. Mol. Pharmacol. (1999) 55(3):453-461.
7. GASPARINI F, KUHN R, PIN JP: Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Current Opin. Pharmacol. (2002) 2:43-49.
8. DE VRY J, HORVATH E, SCHREIBER R: Neuroprotective and behavioural effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. Eur. J. Pharmacol. (2001) 428(2):203-214.
9. CARROLL FY, STOLLE A, BEART PM et al.: BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol. Pharmacol. (2001) 59(5):965-973.
10. SOUDIJN W, VAN WIJNGAARDEN I, IJZERMAN AP: Allosteric modulation of G protein-coupled receptors. Expert Opin. Ther. Patents (2001) 11(12):1889-1904.
11. IJZERMAN A, KOUROUNAKIS A, VAN DER KLEIN P: Allosteric modulation of G protein-coupled receptors. Farmaco. (2001) 56(1-2):67-70.
12. CHRISTOPOULOS A: Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Review Drug Discovery (2002) 1:198-210.
13. CHRISTOPOULOS A, KENAKIN T: G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. (2002) 54(2):323-374.
14. GASPARINI F, FLOERSHEIM P, FLOR PJ et al.: Discovery and characterization of non-competitive antagonists of group I metabotropic glutamate receptors. Farmaco. (2001) 56(1-2):95-99.
15. KNOFLACH F, MUTEL V, JOLIDON S et al.: Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action and binding site. Proc. Natl. Acad. Sci. USA. (2001) 98(23):13402-13407.
16. GASPARINI F, LINGENHOHL K, STOEHR N et al.: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology (1999) 38(10):1493-1503.
17. VARNEY MA, COSFORD ND, JACHEC C et al.: SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor Type 5. J. Pharmacol. Exp. Ther. (1999) 290(1):170-181.
18. WALKER K, BOWES M, PANESAR M et al.: Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology (2001) 40(1):1-9.
19. WALKER K, REEVE A, BOWES M et al.: mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurons mediate inflammatory hyperalgesia. Neuropharmacology (2001) 40(1):10-19.
20. BHAVE G, KARIM F, CARLTON SM, GEREAU RW 4th: Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat. Neurosci. (2001) 4(4):417-423.
21. KARIM F, BHAVE G, GEREAU RW 4th: Metabotropic glutamate receptors on peripheral sensory neuron terminals as targets for the development of novel analgesics. Mol. Psychiatry (2001) 6(6):615-617.
22. SPOOREN WP, VASSOUT A, NEIJT HC et al.: Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. (2000) 295(3):1267-1275.
23. SCHULZ B, FENDT M, GASPARINI F, LINGENHOHL K, KUHN R, KOCH M: The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology (2001) 41(1):1-7.
24. CHIAMULERA C, EPPING-JORDAN MP. ZOCCHI A et al.: Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. (2001) 4(9):873-874.
25. GATTI S, KNOFLACH F, KEW JNC et al.: 8-phenyethynyl-1,3Dihydrobenzo [b] [1,4] diazepin-2one derivatives are potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Soc. Neurosci. Abst. (2001) 27: 705.10
26. BALLARD TM, KEW JNC, RICHARDS JG et al.: Pharmacological and genetic evidence for an important modulatory role of mGlu2 receptors on cognitive function. Soc. Neurosci. Abst. (2001) 27: 705.11